- Home
- REFR vs ESLA Comparison
REFR vs ESLA Comparison
Compare REFR & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFR | ESLA |
|---|---|---|
| Founded | 1965 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.8M | 48.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | REFR | ESLA |
|---|---|---|
| Price | $1.62 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 60.0K | ★ 243.3K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,227,276.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $0.73 |
| 52 Week High | $2.70 | $3.15 |
Technical Indicators
Market Signals| Indicator | REFR | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 50.90 |
| Support Level | $1.85 | $1.52 |
| Resistance Level | $2.10 | $2.27 |
| Average True Range (ATR) | 0.17 | 0.31 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 17.24 | 59.04 |
Price Performance
Historical ComparisonAbout REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.